Table 3 Immunohistochemical markers that significantly differentiate non-BRCA1/2 tumors with and without somatic BRCA1 inactivation (promoter hypermethylation and LOH of the BRCA1 allele), and comparisons with BRCA1 tumors

From: Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families

 

Non-BRCA1/2 tumors without somatic BRCA1 inactivation (n=41) (%)

P*

Non-BRCA1/2 tumors with somatic BRCA1 inactivation (n=7) (%)

P**

BRCA1 tumors (n=33) (%)

P***

Grade

 1

23 (63.9)

 

0

0.2

0

 

 2

8 (22.2)

 

0

 

5 (16.1)

 

 3

5 (13.9)

<0.001

6 (100.0)

 

26 (83.9)

<0.001

ER

 Negative

14 (34.1)

 

6 (85.7)

0.4

23 (71.9)

 

 Positive

27 (65.9)

0.011a

1 (14.3)

 

9 (28.1)

0.001

PR

 Negative

15 (36.6)

 

7 (100.0)

0.1

26 (78.8)

 

 Positive

26 (63.4)

0.002

0

 

7 (21.2)

<0.001

BCL2

 Negative

20 (48.8)

 

7 (100.0)

0.2

28 (84.8)

 

 Positive

21 (51.2)

0.012a

0

 

5 (15.2)

0.001

Ki-67

 0–5%

32 (78.0)

 

1 (14.3)

0.6

9 (27.3)

 

 6–25%

7 (17.1)

 

2 (28.6)

 

11 (33.3)

 

 >25%

2 (4.9)

<0.001

4 (57.1)

 

13 (39.4)

<0.001

p53

 Negative

38 (92.7)

 

3 (42.9)

0.6

17 (51.5)

 

 Positive

3 (7.3)

0.001

4 (57.1)

 

16 (48.5)

<0.001

Cyclin E

 Negative

35 (85.4)

 

2 (28.6)

0.3

15 (46.9)

 

 Positive

6 (14.6)

0.001

5 (71.4)

 

16 (53.1)

<0.001

Cyclin A

 Negative

29 (70.7)

 

0

0.3

4 (12.1)

 

 Positive

12 (29.3)

<0.001

7 (100.0)

 

29 (87.9)

<0.001

p27

 Negative

16 (40.0)

 

6 (85.7)

0.2

21 (63.6)

 

 Positive

24 (60.0)

0.025a

1 (14.3)

 

12 (36.4)

0.044a

Skp2

 Negative

25 (62.5)

 

0

0.2

5 (15.6)

 

 Positive

15 (37.5)

0.002

7 (100.0)

 

27 (84.4)

<0.001

CHEK2

 Negative

26 (83.9)

 

3 (42.9)

1.0

12 (42.9)

 

 Positive

5 (16.1)

0.021a

4 (57.1)

 

16 (57.1)

0.001

CK5/6

 Negative

40 (97.6)

 

5 (71.4)

0.4

19 (57.6)

 

 Positive

1 (2.4)

0.008a

2 (28.6)

 

14 (42.4)

<0.001

CK8

 Negative

4 (10.0)

 

5 (71.4)

0.4

18 (54.5)

 

 Positive

36 (90.0)

<0.001

2 (28.6)

 

15 (45.5)

<0.001

Vimentin

 Negative

35 (92.1)

 

2 (28.6)

0.3

15 (46.9)

 

 Positive

3 (7.9)

<0.001

5 (71.4)

 

17 (53.1)

<0.001

Survivin

 Negative

29 (80.6)

 

1 (14.3)

0.1

12 (42.9)

 

 Positive

7 (19.4)

<0.001

6 (85.7)

 

16 (57.1)

0.002

EGFR

 Negative

33 (97.1)

 

2 (28.6)

0.2

15 (53.6)

 

 Positive

1 (2.9)

<0.001

5 (71.4)

 

13 (46.4)

<0.001

  1. ER, estrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor.
  2. aNo longer significant after correcting for multiple testing.
  3. *P-value for comparison between non-BRCA1/2 without and with somatic BRCA1 inactivation.
  4. **P-value for comparison between non-BRCA1/2 with somatic BRCA1 inactivation and BRCA1 tumors.
  5. ***P-value for comparison between non-BRCA1/2 without somatic BRCA1 inactivation and BRCA1 tumors.
Back to article page